@ Halal | September-October . 2024

Leading the charge in halal pharmaceuticals with global innovation

BY SHEILA ROZARIO

“ One major challenge is the high risk of failure in clinical trials or bioequivalence studies due to the inherent complexity of these products . Navigating the diverse requirements and regulations set by various regulatory bodies and authorities adds another layer of complexity ,” said Novugen Chief Executive Officer Rahil Mahmood .

The financial burden is also considerable . Developing these complex generics demands substantial capital investment , covering research , development , advanced manufacturing technologies , and regulatory compliance . Beyond financial challenges , the demand for highly skilled professionals and the need to maintain scientific competency significantly impact the feasibility and success of these endeavours .

Despite these obstacles , Novugen has made significant strides .

“ Over the years , we have taken calculated risks to ensure early market access for complex products , providing patients with treatments when there are no robust alternatives available ,” Rahil noted .

The company ’ s strategy has paid off , with several first-to-market products introduced in Malaysia and the US , reflecting their commitment to overcoming challenges and delivering innovative solutions .

GLOBAL COMPETITIVENESS IN R & D

In a rapidly evolving pharmaceutical landscape , innovation is vital to maintaining a competitive edge . Novugen ’ s approach to research and development ( R & D ) is both strategic and forward-thinking .

“ We make significant investments in developing advanced and challenging products , particularly in high-value areas like oncology ,” Rahil shared .

The company ’ s focus on complex therapeutic areas with substantial entry barriers positions it as a leader in pharmaceutical innovation .

“ By leveraging cutting-edge technologies and investing in state-of-the-art platforms , Novugen aligns its R & D efforts with the future of healthcare .”

MALAYSIA ’ S STRATEGIC ROLE

Malaysia holds a central role in Novugen ’ s business strategy , serving as both its global R & D hub and a significant manufacturing base .

“ We have strategically established Malaysia as our global R & D hub , equipped with a 40,000-square-foot R & D centre that employs over a hundred local scientists along with hundreds of other local professionals ,” Rahil highlighted .

In addition to its R & D capabilities , Novugen operates two USFDA-approved manufacturing facilities in the country .

Looking ahead , Malaysia will continue to be pivotal to Novugen ’ s long-term strategy . The country is poised to be the company ’ s R & D and manufacturing hub for export markets , including the US , the largest pharmaceutical

Novugen Pharma Manufacturing Facility .

Novugen Oncology Manufacturing Facility . market in the world .

Novugen is committed to developing a comprehensive ecosystem in Malaysia by nurturing local talent , collaborating with third-party vendors , and expanding its manufacturing capacities .

“ Our goal is to elevate Malaysia ’ s position on the global stage and ensure its integral role in our business strategy .”

IMPACT OF HALAL CERTIFICATION

For Novugen , halal certification is not just a compliance matter ; it is a cornerstone of its market strategy .

“ Halal certification significantly

“ Over the years , we have taken calculated risks to ensure early market access for complex products , providing patients with treatments when there are no robust alternatives available .”

– Rahil Mahmood influences consumer trust by ensuring that our products comply with Islamic ethical standards ,” Rahil asserted .

This certification builds strong loyalty among Muslim consumers and enhances market penetration in regions with substantial Muslim populations .

Novugen stands out as the first to have a USFDA-approved and halal-compliant manufacturing facility , a dual achievement that amplifies its commitment to quality and adherence to Islamic standards .

Rahil believes that this strategic positioning enables Novugen to tap into diverse consumer bases and strengthen our presence in international markets .

PIONEERING ONCOLOGY AND INNOVATIONS

Novugen has placed significant emphasis on oncology , a field that Rahil describes as one of the most dynamic and rapidly evolving fields in medical research .

“ Cancer continues to be a leading cause of disease burden worldwide , partly due to changing lifestyles , increased stress levels , and global pollution . As the prevalence of cancer rises , there is a significant opportunity for pharmaceutical companies to develop and bring innovative treatments to the market .”

The company has focused its efforts on developing high-potent oncology drugs that address unmet needs in cancer treatment , contributing to the global fight against this devastating disease .

Looking forward , Novugen has ambitious plans . “ Over the next two to three years , we will be filing dossiers in various markets across Southeast Asia , the Middle East , Central Asia , Africa , Europe , Canada , and Australia .

“ We are also forging strategic partnerships to leverage our R & D expertise in developing biosimilars and biologics ,” Rahil shared .

The company is also advancing its capabilities in injectables and soft gels , and exploring new technologies . With a focus on staying at the forefront of pharmaceutical innovation , Novugen is poised to continue its growth and impact on a global scale . –